

UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

J. M. Lowe
Signature of Authorized Individual*

6/19/2020
Date

JOD LOWE
Printed Name of Authorized Individual

6/19/2020
Date

*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)

Case No.	Debtor Entity Name:	Net Receipts ²	Net Disbursements ¹
19-23648	PURDUE PHARMA INC.	\$ 106,667	\$ 267,291
19-23649	PURDUE PHARMA L.P.	124,704,674	69,748,296
19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	-
19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	3,050
19-23652	PURDUE PHARMACEUTICALS L.P.	-	2,836,848
19-23653	IMBRIUM THERAPEUTICS L.P.	807	1,345,389
19-23654	ADLON THERAPEUTICS L.P.	-	3,151,152
19-23655	GREENFIELD BIO VENTURES L.P.	-	-
19-23656	SEVEN SEAS HILL CORP.	-	-
19-23657	OPHIR GREEN CORP.	-	-
19-23658	PURDUE PHARMA OF PUERTO RICO	-	2,113
19-23659	AVRIO HEALTH L.P.	59,895	4,753,165
19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	10,301
19-23661	PURDUE NEUROSCIENCE COMPANY	-	-
19-23662	NAYATT COVE LIFESCIENCE INC.	-	-
19-23663	BUTTON LAND L.P.	-	-
19-23664	PAUL LAND INC.	-	-
19-23665	QUIDNICK LAND L.P.	-	-
19-23666	RHODES ASSOCIATES L.P.	-	-
19-23667	RHODES PHARMACEUTICALS L.P.	15,830,491	22,622,020
19-23668	RHODES TECHNOLOGIES	1,389,161	2,883,792
19-23669	UDF LP	-	-
19-23670	SVC PHARMA LP	-	398,577
19-23671	SVC PHARMA INC.	-	-
Totals:		\$ 142,091,694	\$ 108,021,993

Footnotes

1) The Net Disbursements exclude intercompany transactions among Debtors

2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
May 31, 2020

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	\$ 750,229
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxxx2400	Escrow	10,863,311
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,020,145
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	3,507,022
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,663,331
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Money Market Account	201,273,014
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Money Market Account	100,296,603
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx8720	Money Market Account	100,189,223
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxxx8266	Money Market Fund	53,818,111
Purdue Pharma L.P.	Goldman Sachs #506	xxxxx0462	Money Market Fund	645,504,418
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	21,874,127
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	186,723
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx6017	Trust	15,147,370
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxxx1100	Trust	10,271,428
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxxx6600	Trust	59,169,425
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,017,014
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	125,324,030
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxxx0300	Trust	10,389,911
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx4018	Trust	25,102,879
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	925,525
Purdue Pharma Inc.	JP Morgan Chase	xxxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxxx5300	Trust	125,905
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxxx3154	Money Market Fund	-

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
May 31, 2020

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxxx3153	Money Market Fund	-
Rhodes Technologies	JP Morgan Chase	xxxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
Total				\$ 1,408,770,409

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

CONSOLIDATED STATEMENT OF OPERATIONS (\$M)^{1,2}
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date ³
Net Sales	\$ 61	\$ 399	\$ 710
Cost of Goods Sold	(5)	(68)	(68)
Royalty Expense	1	(7)	(7)
Shipping and Warehousing	(1)	(2)	(2)
Cost of Goods Sold	(5)	(77)	(177)
Gross Profit	57	323	533
Sales and Promotion	(8)	(46)	(84)
Research and Development	(4)	(27)	(61)
General and Administrative	(7)	(40)	(80)
Legal Fees - Ordinary Course	(2)	(5)	(8)
Medical Affairs	(4)	(14)	(25)
Milestones & Alliances	-	(4)	(5)
Health Care Reform Fee	(1)	(4)	(8)
Other US	1	(1)	(2)
Incentive Bonus	(3)	(17)	(33)
Insurance Income	-	-	-
Settlement Expense	-	-	-
Total Operating Expenses	(28)	(158)	(306)
Operating Profit	29	165	228
Legal Fees - Non-Recurring	(35)	(144)	(241)
Other	(5)	(5)	(12)
Total Non-Operating Expenses	(40)	(149)	(253)
Profit	\$ (11)	\$ 16	\$ (25)

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000) ^{1,2}

	Current Month	2020 Year to Date	2019 Cumulative Filing to Date ³
Management Fee Income	\$ 29	\$ 146	\$ 261
General and Administrative Expenses	(1)	(22)	(51)
Operating Income	28	124	210
Other income:	-	-	-
Income from Unconsolidated Associated Companies	(24)	109	(817)
Interest income - associated companies	-	-	-
Total Other Income	(24)	109	(817)
Pre-Tax Income	4	233	(607)
Income Tax Provision	(1)	(63)	149
Net Income	\$ 3	\$ 170	\$ (458)

Footnotes

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
May 31, 2020

CONSOLIDATED BALANCE SHEET (\$M) ^{1,2}	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
ASSETS	
CURRENT ASSETS	
Cash & Cash Equivalents	\$ 1,122
Available For Sale Investments	1
Accounts Receivable, Net	77
Due From Associated Companies	6
Other Receivables	4
Inventories, Net	106
Prepaid Expenses & Other Current Assets	52
Restricted Cash	236
TOTAL CURRENT ASSETS	1,604
Property and Equipment, net	138
Investments at Cost	36
Investments in Associated Companies	(1)
Restricted Cash - Long-Term	49
Intangible Assets, Net	99
Other Assets	12
TOTAL ASSETS	\$ 1,937
LIABILITIES AND EQUITY	
CURRENT LIABILITIES	
Accounts Payable	\$ 45
Accrued Expenses	363
Due to Associated Companies	1
TOTAL CURRENT LIABILITIES	409
Other Liabilities	98
Due to Associated Companies	11
Liabilities Subject to Compromise ³	3,018
TOTAL LIABILITIES	3,536
EQUITY	
Retained Earnings & Partners' Capital	(1,554)
Accumulated Other Comprehensive Loss	(45)
TOTAL EQUITY	(1,599)
TOTAL LIABILITIES AND EQUITY	\$ 1,937

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
May 31, 2020

PURDUE PHARMA, INC. BALANCE SHEET (\$000) ^{1,2}

	Book Value
Assets	
Currents assets:	
Cash and cash equivalents	\$ 926
Prepaid expenses	312
Due from Associated Companies	431
Other receivables	-
Total current assets	1,669
Investments	10,430
Deferred income taxes	147
Total assets	\$ 12,246
Liabilities and equity	
Current liabilities:	
Accounts payable	\$ 463
Due to Associated Companies	383
Accrued Expenses	178
Total liabilities	1,024
Common stock	1
Additional paid-in capital	499
Retained earnings	10,787
Accumulated other comprehensive loss	(65)
Total equity	11,222
Total liabilities and equity	\$ 12,246

Footnotes

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020


SCHEDULE OF POST PETITION TAXES

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



Signature

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
Compensation		
Chomiak, Caroline	\$ 54,231	\$ 261,662
Kesselman, Marc L ²	245,256	2,459,835
Landau, Craig J	399,393	2,144,608
Lowne, Jonathan R	125,678	1,146,787
Lundie, David R	100,261	941,228
Mancinelli II, Vincent F	61,562	550,156
Mazzi, Christian	-	439,030
Medeiros, Paul	84,142	741,063
Shamblen, Randy	60,255	540,673
Strassburger, Philip C	116,553	975,569
Total Compensation	1,247,331	10,200,611
Director Fees		
Boer, F Peter	-	525,000
Buckfire, Kenneth A	-	525,000
Cola, Michael	-	525,000
Collins, Michael J	-	25,000
Dubel, John	-	525,000
Miller, Robert S	208,333	1,458,333
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	-	525,000
Total Director Fees	208,333	4,133,333
T&E Reimbursements		
Boer, F Peter	-	10,907
Buckfire, Kenneth A	-	1,179
Chomiak, Caroline	-	30,408
Cola, Michael	-	1,388
Debone, Louis	-	1,245
Dubel, John	-	4,714
Kesselman, Marc L	422	49,315
Landau, Craig J	-	64,293
Lowne, Jonathan R	-	1,764
Lundie, David R	-	28,363
Mancinelli II, Vincent F	313	41,201
Mazzi, Christian	-	3,734
Medeiros, Paul	(929)	38,008
Miller, Robert S	-	9,765
Pickett, Cecil	-	1,298
Shamblen, Randy	566	11,431
Strassburger, Philip C	-	15,715
Total T&E Reimbursements	371	314,727
Housing Payments		
Kesselman, Marc L	4,673	46,503
Total Housing Payments	4,673	46,503

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
Indemnification Payments		
Baker, Stuart D	570,995	570,995
Butcher, James A	-	527
Friedman, Michael	-	136,498
Landau, Craig J	140,685	837,894
Motahari, Saeed	-	14,565
Roncalli, Anthony	70,063	70,063
Stewart, John	7,615	91,055
Timney, Mark	108,378	1,032,903
Purdue Pharma Inc Independent Directors ³	87,302	790,843
Total Indemnification Payments	985,040	3,545,344
Payments to Independent Associated Companies		
Mundibiopharma Ltd	-	55,332
Mundipharma DC BV	204,981	204,981
Mundipharma International Technical Operations Ltd.	4,479	4,479
Mundipharma IT Services LTD	24,757	278,603
Mundipharma Laboratories GmbH	-	271,128
Mundipharma Research LTD	-	63,532
Mundipharma Singapore Holdings Pte Ltd	-	60,675
One Stamford Realty L.P.	735,877	6,397,032
Pharmaceutical Research Associates Inc.	442,682	485,533
Purdue Pharma Canada	578,471	3,040,209
TXP Services Inc. ⁴	440,112	5,022,407
Total Payments to Independent Associated Companies	2,431,360	15,883,910
Total Payments to Insiders	\$ 4,877,108	\$ 34,124,427

Footnotes

- 1) Represents payments made since the Commencement Date.
- 2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.
- 3) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snyderman, Ralph.
- 4) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ^{1,2}
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	\$ 3,831,762	\$ 27,099,321
AlixPartners, LLP	1,245,091	5,705,968
PJT Partners LP	-	782,456
Prime Clerk LLC	-	35,561,072
Total Estate Professionals	5,076,853	69,148,818
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	2,663,697	10,700,026
Bayard, P.A.	507,408	768,164
Cole Schotz P.C.	264,409	264,409
Jefferies LLC	188,953	984,157
KPMG	360,305	825,351
Province, Inc.	913,657	4,837,425
Kurtzman Carson Consultants LLC	-	23,735
Total Creditor Committee Professionals	4,898,429	18,403,267
<i>Ad Hoc Committee Professionals</i>		
Kramer Levin Naftalis & Frankel LLP	349,646	2,505,169
Brown Rudnick LLP	415,919	1,335,171
Gilbert LLP	90,734	870,501
Otterbourg PC	153,879	602,555
FTI Consulting, Inc	498,212	3,060,059
Compass Lexecon	-	-
Coulter & Justice	-	-
Total Ad Hoc Committee Professionals	1,508,390	8,373,455
<i>Special Counsel to the Debtors</i>		
Arnold Porter & Kaye Scholer	44,116	630,683
Dechert LLP	-	-
Jones Day	244,564	1,116,723
King & Spalding LLP	1,040,221	5,295,186
Skadden, Arps, Slate, Meagher & Flom LLP	-	3,148,222
Wilmer Cutler Pickering Hale and Door LLP	-	-
Total Special Counsel Professionals	1,328,901	10,190,814
The Law Offices of Kenneth Feinberg (Mediator)	500,000	1,502,648
Phillips ADR (Mediator)	500,000	1,504,089
Bielli & Klauder, LLC (Fee Examiner)	-	-
Tom Vilsack (Court appointed monitor)	18,000	55,625
Ernst & Young (Canada), Court Appointed Information Officer	-	178,591
Total Retained Restructuring Professional Fees	\$ 13,830,574	\$ 109,357,306

Footnotes

- 1) Represents payments made since the Commencement Date
- 2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period May 1, 2020 to May 31, 2020

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?		X	
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	